ArticleTheranostics2012
Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin α(v)β(3)-Targeted Radiotracer( 99m)Tc-3P-RGD(2).
Article in Theranostics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.Theranostics · 2018Article
- Evaluation ofAnnals of nuclear medicine · 2017Article
- Negative feedback between TAp63 and Mir-133b mediates colorectal cancer suppression.Oncotarget · 2016Article
- Comparison of biological properties ofNuclear medicine and biology · 2016Article
- Comparison of the accuracy ofOncology letters · 2016Article
- A pH-Responsive Host-guest Nanosystem Loading Succinobucol Suppresses Lung Metastasis of Breast Cancer.Theranostics · 2016Article
- Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins.Bioconjugate chemistry · 2015Review
- Influence of mesenchymal stem cells on metastasis development in mice in vivo.Stem cell research & therapy · 2015Article
- Evaluation of ανβ3-mediated tumor expression with a 99mTc-labeled ornithine-modified RGD derivative during glioblastoma growth in vivo.Cancer biotherapy & radiopharmaceuticals · 2014Article
- Impact of multiple negative charges on blood clearance and biodistribution characteristics of 99mTc-labeled dimeric cyclic RGD peptides.Bioconjugate chemistry · 2014Article
- Comparison of three dimeric 18F-AlF-NOTA-RGD tracers.Molecular imaging and biology · 2014Article
- [Radio-labeling of T7 peptide with 99mTc and its biodistribution in nude mice bearing non-small cell lung cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2014Article
- U-SPECT-BioFluo: an integrated radionuclide, bioluminescence, and fluorescence imaging platform.EJNMMI research · 2014Article
- The role of molecular imaging in diagnosis of deep vein thrombosis.American journal of nuclear medicine and molecular imaging · 2014Review
- (99m)Tc-Galacto-RGD2: a novel 99mTc-labeled cyclic RGD peptide dimer useful for tumor imaging.Molecular pharmaceutics · 2013Article
- Targeted delivery of antisense oligonucleotides by chemically self-assembled nanostructures.Molecular pharmaceutics · 2013Article
- Monitoring tumor response to linifanib therapy with SPECT/CT using the integrin αvβ3-targeted radiotracer 99mTc-3P-RGD2.The Journal of pharmacology and experimental therapeutics · 2013Article
- Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: paving the way for molecular imaging.Cellular oncology (Dordrecht, Netherlands) · 2013Article
- Evaluation of K(HYNIC)(2) as a bifunctional chelator for (99m)Tc-labeling of small biomolecules.Bioconjugate chemistry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe purpose of this study was to evaluate the capability of u-SPECT-II/CT to monitor the progression of breast cancer lung metastasis using (99m)Tc-3P-RGD(2) as a radiotracer.
methodsThe breast cancer lung metastasis model was established by tail-vein injection of 2 x 10(5) - 1.5 x 10(6) MDA-MB-231 cells into each athymic nude mouse. SPECT/CT studies were performed at a specified time after inoculation of MDA-MB-231 cells. Histological staining was used to further confirm the presence of lung metastases.
resultsWe found that both inoculation time and tumor cell load had significant influence on the extent of lung metastasis. For example, if animals were injected with 2 x 10(5) MDA-MB-231 cells, there were no detectable metastatic breast tumors in the lungs after 8 weeks. If animals were injected with 1 x 10(6) MDA-MB-231 cells, there were many tumors in both lungs at week 8. When 1.5 x 10(6) MDA-MB-231 cells were injected, the animal became very weak by week 7. We also found a rare example of breast cancer metastasis in the muscle and mediastinal lymph nodes. The tumor necrotic regions were clearly delineated by u-SPECT-II/CT.
conclusionThis study clearly demonstrated that (99m)Tc-3P-RGD(2) is an excellent radiotracer for noninvasive imaging of metastatic breast tumors in the lungs, mediastinal lymph nodes and muscles. (99m)Tc-3P-RGD(2) SPECT/CT is an outstanding platform for monitoring the progression of breast cancer lung metastases, semi-quantification of breast tumor load in the lungs and delineation of tumor necrosis in small animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.